Italy's antitrust regulator fined Novartis and Roche €182.5 million for allegedly colluding to prevent the use of Roche's Avastin, a cancer drug, as a treatment for eye macular degeneration. The two pharmaceutical companies blocked distribution of Avastin in favor of a more expensive drug, Lucentis, which they marketed jointly for ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
To continue reading this article register now.